Extraordinary General Meeting - Active Biotech AB


The EGM approved the Board's decision to issue a debenture loan at a nominal amount of SEK 149,950,560 through the issue of 3,748,764 convertible debentures.
The convertible debentures shall convey the right for conversion into shares in the Company, each with a par value of SEK 10. Through conversion, the share capital in the Company may be increased by 37,487,640. The loan will carry 2 percent interest from January 1, 2005 and will mature for payment on June 30, 2009, if the debentures have not been converted by that time.
Preferential rights to subscribe for debentures shall be given to existing shareholders, with each nine shares currently held entitling shareholders to subscribe for one convertible debenture. In the event that not all convertible debentures are subscribed through preferential rights, the Board will decide on allocation within the framework of the total amount of the issue.

The conversion price will be SEK 40. The record date for participation in the issue will be November 15, 2004. Subscription and payment are to take place during the period November 19, 2004 to December 9, 2004.
MGA Holding AB, with shares corresponding to 28.9 percent of the share capital and voting rights, has guaranteed that the entire issue will be subscribed.
Lund 9 November, 2004
Active Biotech (publ)
Sven Andréasson
President & CEO
Active Biotech AB is a biotechnology company focusing on research in and development of pharmaceuticals. Active Biotech has a strong research portfolio and pipeline products with focus primarily on autoimmune/inflammatory diseases and cancer. Most advanced projects involve unique substances with immunomodulatory properties (SAIK-MS) intended for the treatment of multiple sclerosis, as well as a novel concept for cancer immunotherapy (TTS).
Active Biotech AB
Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 20 50